- Home
- Publications
- Publication Search
- Publication Details
Title
Improving clinical trial outcomes in amyotrophic lateral sclerosis
Authors
Keywords
-
Journal
Nature Reviews Neurology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-18
DOI
10.1038/s41582-020-00434-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis
- (2020) William Huynh et al. Expert Review of Neurotherapeutics
- Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis
- (2020) Michael Swash et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study)
- (2020) Steve Vucic et al. MEDICINE
- ALS is a multistep process in South Korean, Japanese, and Australian patients
- (2020) Steve Vucic et al. NEUROLOGY
- A proposal for new diagnostic criteria for ALS
- (2020) Jeremy M. Shefner et al. CLINICAL NEUROPHYSIOLOGY
- Tamoxifen for amyotrophic lateral sclerosis
- (2020) Po-Chih Chen et al. MEDICINE
- The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis
- (2020) Christian Lunetta et al. JOURNAL OF NEUROLOGY
- Great expectations: virus-mediated gene therapy in neurological disorders
- (2020) Didu Kariyawasam et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS
- (2020) Christian Mueller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
- (2020) Timothy Miller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial
- (2020) William Camu et al. EBioMedicine
- Long‐Term Survival of Participants in the CENTAUR Trial of Sodium Phenylbutyrate‐Taurursodiol in ALS
- (2020) Sabrina Paganoni et al. MUSCLE & NERVE
- Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
- (2020) Sabrina Paganoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS
- (2020) Jeremy M. Shefner et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis
- (2020) Brian J. Wainger et al. JAMA Neurology
- Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study
- (2019) Ryuji Kaji et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial
- (2019) R.S. Bedlack et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
- (2019) Leonard H. van den Berg et al. NEUROLOGY
- Measuring network disruption in neurodegenerative diseases: New approaches using signal analysis
- (2019) Roisin McMackin et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Validation of the revised classification of cognitive and behavioural impairment in ALS
- (2019) Barbara Iazzolino et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Challenges with Novel Clinical Trial Designs: Master Protocols
- (2019) Michael Cecchini et al. CLINICAL CANCER RESEARCH
- Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
- (2019) Maria Pia Sormani et al. Annals of Clinical and Translational Neurology
- Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial
- (2019) Ammar Al-Chalabi et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Amyotrophic lateral sclerosis: Origins traced to impaired balance between neural excitation and inhibition in the neonatal period
- (2019) Matthew C. Kiernan et al. MUSCLE & NERVE
- Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial
- (2019) Julian Gold et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial
- (2019) Jesus S. Mora et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis
- (2019) Suma Babu et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Early focality and spread of cortical dysfunction in amyotrophic lateral sclerosis: A regional study across the motor cortices
- (2019) Thanuja Dharmadasa et al. CLINICAL NEUROPHYSIOLOGY
- Human cerebral evolution and the clinical syndrome of amyotrophic lateral sclerosis
- (2018) Robert D Henderson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study
- (2018) Ton Fang et al. LANCET NEUROLOGY
- Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model
- (2018) Henk-Jan Westeneng et al. LANCET NEUROLOGY
- Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial
- (2018) Albert C Ludolph et al. LANCET NEUROLOGY
- Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial
- (2018) Björn Oskarsson et al. MUSCLE & NERVE
- Advances in therapy for spinal muscular atrophy: promises and challenges
- (2018) Ewout J. N. Groen et al. Nature Reviews Neurology
- Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressiveSOD1ALS
- (2018) Michael Benatar et al. NEUROLOGY
- TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole
- (2018) Moritz Oberstadt et al. Scientific Reports
- Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis
- (2018) Rebecca K. Sheean et al. JAMA Neurology
- Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS
- (2018) Stephen A. Goutman et al. Annals of Clinical and Translational Neurology
- Rasagiline for Amyotrophic Lateral Sclerosis: a Randomized Controlled Trial
- (2018) Jeffrey M Statland et al. MUSCLE & NERVE
- ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
- (2018) Christopher Crockford et al. NEUROLOGY
- Psychiatric disorders in C9orf72 kindreds
- (2018) Emma M. Devenney et al. NEUROLOGY
- Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy
- (2018) Leonela Amoasii et al. SCIENCE
- Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
- (2018) Peter Connick et al. BMJ Open
- Therapeutic Oligonucleotides: State of the Art
- (2018) C.I. Edvard Smith et al. Annual Review of Pharmacology and Toxicology
- Medical conferences: value for money?
- (2018) Michael Swash et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis
- (2018) Federico Verde et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- ALS longitudinal studies with frequent data collection at home: study design and baseline data
- (2018) Seward B. Rutkove et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Drugs in clinical development for the treatment of amyotrophic lateral sclerosis
- (2017) Ana Martinez et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Genetic screening in sporadic ALS and FTD
- (2017) Martin R Turner et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Fasciculation in amyotrophic lateral sclerosis: origin and pathophysiological relevance
- (2017) Mamede de Carvalho et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials
- (2017) Ruben P A van Eijk et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Cortical influences drive amyotrophic lateral sclerosis
- (2017) Andrew Eisen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker
- (2017) Jan Kassubek et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis
- (2017) Maxim De Schaepdryver et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
- (2017) Koji Abe et al. LANCET NEUROLOGY
- Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials
- (2017) Ruben P.A. van Eijk et al. NEUROLOGY
- Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial
- (2017) Richard Smith et al. Neurotherapeutics
- Amyotrophic Lateral Sclerosis
- (2017) Robert H. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis
- (2017) Tania F. Gendron et al. Science Translational Medicine
- Comparison of the King’s and MiToS staging systems for ALS
- (2017) Ton Fang et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- July 2017 ENCALS statement on edaravone
- (2017) Ammar Al-Chalabi et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Clustering of Neuropsychiatric Disease in First-Degree and Second-Degree Relatives of Patients With Amyotrophic Lateral Sclerosis
- (2017) Margaret O’Brien et al. JAMA Neurology
- Assessment of the upper motor neuron in amyotrophic lateral sclerosis
- (2016) William Huynh et al. CLINICAL NEUROPHYSIOLOGY
- Efficiencies of platform clinical trials: A vision of the future
- (2016) Benjamin R Saville et al. Clinical Trials
- New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel
- (2016) Leslie A Rudzinski et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Neuronal network disintegration: common pathways linking neurodegenerative diseases
- (2016) Rebekah M Ahmed et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Amyotrophic lateral sclerosis: moving towards a new classification system
- (2016) Ammar Al-Chalabi et al. LANCET NEUROLOGY
- Pathophysiological and diagnostic implications of cortical dysfunction in ALS
- (2016) Nimeshan Geevasinga et al. Nature Reviews Neurology
- Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience
- (2016) Jerome Mertens et al. NATURE REVIEWS NEUROSCIENCE
- A randomized trial of mexiletine in ALS
- (2016) Michael D. Weiss et al. NEUROLOGY
- Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis
- (2016) Ricarda A. L. Menke et al. Neurotherapeutics
- Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS
- (2016) Nimeshan Geevasinga et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes
- (2015) Rachel H. Tan et al. BRAIN
- The MITOS system predicts long-term survival in amyotrophic lateral sclerosis
- (2015) Irene Tramacere et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Rate of disease progression: a prognostic biomarker in ALS
- (2015) Julie Labra et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study
- (2015) Parvathi Menon et al. LANCET NEUROLOGY
- How common are ALS plateaus and reversals?
- (2015) Richard S. Bedlack et al. NEUROLOGY
- Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
- (2015) C.-H. Lu et al. NEUROLOGY
- Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?
- (2015) Katharine A. Nicholson et al. Neurotherapeutics
- Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis
- (2015) Seward B. Rutkove Neurotherapeutics
- A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement
- (2015) Zachary Macchi et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial
- (2015) Susanna B. Park et al. EBioMedicine
- Quantifying disease progression in amyotrophic lateral sclerosis
- (2014) Neil G. Simon et al. ANNALS OF NEUROLOGY
- Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials
- (2014) Rubika Balendra et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Amyotrophic lateral sclerosis: a long preclinical period?
- (2014) A. Eisen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial
- (2014) Merit E Cudkowicz et al. LANCET NEUROLOGY
- Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders
- (2014) Lindsay C. Burrage et al. MOLECULAR GENETICS AND METABOLISM
- The PRO-ACT database: Design, initial analyses, and predictive features
- (2014) N. Atassi et al. NEUROLOGY
- Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies
- (2014) Steve Vucic et al. TRENDS IN NEUROSCIENCES
- Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-Derived Motor Neurons
- (2014) Brian J. Wainger et al. Cell Reports
- ALSUntangled No. 26: Lunasin
- (2014) Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: A population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis
- (2013) Susan Byrne et al. ANNALS OF NEUROLOGY
- Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis
- (2013) Steve Vucic et al. BRAIN
- S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis
- (2013) Richard J. Mead et al. FREE RADICAL BIOLOGY AND MEDICINE
- Pathophysiological insights into ALS with C9ORF72 expansions
- (2013) K. L. Williams et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
- (2013) Timothy M Miller et al. LANCET NEUROLOGY
- Controversies and priorities in amyotrophic lateral sclerosis
- (2013) Martin R Turner et al. LANCET NEUROLOGY
- The epidemiology of ALS: a conspiracy of genes, environment and time
- (2013) Ammar Al-Chalabi et al. Nature Reviews Neurology
- Analysis of start-up, retention, and adherence in ALS clinical trials
- (2013) N. Atassi et al. NEUROLOGY
- Alzheimer disease in the United States (2010-2050) estimated using the 2010 census
- (2013) L. E. Hebert et al. NEUROLOGY
- RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention
- (2013) Christopher J. Donnelly et al. NEURON
- Monetary Costs of Dementia in the United States
- (2013) Michael D. Hurd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study
- (2012) Laura Obici et al. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- Online assessment of ALS functional rating scale compares well to in-clinic evaluation: A prospective trial
- (2012) André Maier et al. Amyotrophic Lateral Sclerosis
- Amyotrophic lateral sclerosis
- (2011) Matthew C Kiernan et al. LANCET
- Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm
- (2011) Paul Wicks et al. NATURE BIOTECHNOLOGY
- Clinical diagnosis and management of amyotrophic lateral sclerosis
- (2011) Orla Hardiman et al. Nature Reviews Neurology
- Family history of neurodegenerative and vascular diseases in ALS: A population-based study
- (2011) M. H. B. Huisman et al. NEUROLOGY
- A pilot trial of memantine and riluzole in ALS: Correlation to CSF biomarkers
- (2010) Todd D. Levine et al. Amyotrophic Lateral Sclerosis
- A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis
- (2010) Mamede de Carvalho et al. Amyotrophic Lateral Sclerosis
- Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis
- (2010) Radhia Benmohamed et al. Amyotrophic Lateral Sclerosis
- Arimoclomol: a potential therapy under development for ALS
- (2009) Veena Lanka et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis
- (2009) I. P. Blair et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Scrutinizing enrollment in ALS clinical trials: Room for improvement?
- (2008) Richard S. Bedlack et al. Amyotrophic Lateral Sclerosis
- Phase 2 study of sodium phenylbutyrate in ALS
- (2008) Merit E. Cudkowicz et al. Amyotrophic Lateral Sclerosis
- ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1
- (2008) H. Nishitoh et al. GENES & DEVELOPMENT
- Biomarkers in amyotrophic lateral sclerosis
- (2008) Martin R Turner et al. LANCET NEUROLOGY
- Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis
- (2008) Merit E. Cudkowicz et al. MUSCLE & NERVE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now